At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 242 target
Drug / intervention
filgrastim +10 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin
In Brief
A Phase 3 clinical trial evaluating filgrastim, cytarabine, and 9 other interventions for Lymphoma. Completed, enrolled 242 participants across 10 sites in 3 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesPuerto Rico, Switzerland, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 1994
Primary CompletionSep 2000
First PostedJul 2004
Study CompletionSep 2006
TodayJul 2026
First PostedJul 29, 2004
Enrollment StartDec 1, 1994
Primary CompletionSep 1, 2000
Study CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 21.9 years ago
Interventions
filgrastimbiological
cytarabinedrug
doxorubicin hydrochloridedrug
leucovorin calciumdrug
mercaptopurinedrug
methotrexatedrug
prednisonedrug
vincristine sulfatedrug
low-LET cobalt-60 gamma ray therapyradiation
low-LET electron therapyradiation
low-LET photon therapyradiation